46.05
Schlusskurs vom Vortag:
$45.32
Offen:
$46.05
24-Stunden-Volumen:
779.76K
Relative Volume:
0.54
Marktkapitalisierung:
$6.03B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-507.65M
KGV:
-10.01
EPS:
-4.6
Netto-Cashflow:
$-616.24M
1W Leistung:
-0.88%
1M Leistung:
+2.93%
6M Leistung:
+28.70%
1J Leistung:
-43.19%
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Vergleichen Sie PCVX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
PCVX
Vaxcyte Inc
|
46.05 | 5.93B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Bestätigt | Needham | Buy |
| 2025-09-12 | Eingeleitet | Goldman | Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Why Vaxcyte Inc. (5VA) stock could rally stronglyLong Run Comfort Guide & updated model highlights and notes - ulpravda.ru
How Vaxcyte Inc. (5VA) stock responds to bond market2025 Key Lessons & High Conviction Trade Alerts - ulpravda.ru
Why Vaxcyte Inc. stock could benefit from AI revolutionJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - ulpravda.ru
Why Vaxcyte Inc. stock attracts high net worth investorsJuly 2025 Weekly Recap & Expert Verified Stock Movement Alerts - ulpravda.ru
Is Vaxcyte Inc. (5VA) stock positioned for digital growth eraJuly 2025 Macro Moves & Free Community Consensus Stock Picks - ulpravda.ru
Will Vaxcyte Inc. (5VA) stock test record highs in 20252025 Trade Ideas & Long-Term Growth Plans - ulpravda.ru
Why Vaxcyte Inc. (5VA) stock remains stableMoving Average Strategies & Secret Picks Wall Street Isn’t Talking About - ulpravda.ru
Vaxcyte (PCVX) Gains Positive Outlook with Price Target Boost - GuruFocus
Evercore ISI reiterates Outperform rating on Vaxcyte stock amid CDC changes - Investing.com Canada
Stock Report: Is Vaxcyte Inc stock trading near support levelsSell Signal & Daily Profit Maximizing Trade Tips - moha.gov.vn
Vaxcyte (PCVX) Gains Favor After Immunization Schedule Update - GuruFocus
Vaxcyte, Inc. (PCVX) Stock Analysis: Biotech Innovator With Nearly 100% Upside Potential - DirectorsTalk Interviews
Vaxcyte's Chief Technical Ops Officer Sells Shares - AOL.com
Insider Sell Alert: Harpreet Dhaliwal Sells 9,743 Shares of Vaxc - GuruFocus
Harpreet Dhaliwal Sells 9,743 Shares of Vaxcyte (NASDAQ:PCVX) Stock - MarketBeat
Vaxcyte Inc. (PCVX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Price-Driven Insight from (PCVX) for Rule-Based Strategy - Stock Traders Daily
Vaxcyte, Inc. (NASDAQ:PCVX) Nasdaq Composite Tracks Clinical Progress - Kalkine Media
Vaxcyte shows rising price performance with jump to 81 RS rating - MSN
Trade Alert: Senior Vice President of Finance Of Vaxcyte Elvia Cowan Has Sold Stock - simplywall.st
Vaxcyte (NASDAQ:PCVX) Stock Price Up 3.9%Here's Why - MarketBeat
Vaxcyte Earnings Notes - Trefis
Insider Selling: Vaxcyte (NASDAQ:PCVX) SVP Sells 11,623 Shares of Stock - MarketBeat
Vaxcyte president and CFO sells shares worth $692,100 - MSN
Vaxcyte, Inc. $PCVX Shares Sold by Harbor Capital Advisors Inc. - MarketBeat
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. - Barron's
What Makes Vaxcyte (PCVX) So Attractive - Finviz
What makes Vaxcyte (PCVX) so attractive - MSN
How (PCVX) Movements Inform Risk Allocation Models - Stock Traders Daily
Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Vaxcyte Inc. stock remains resilientJuly 2025 Spike Watch & Weekly Watchlist of Top Performers - Улправда
Assenagon Asset Management S.A. Buys 171,974 Shares of Vaxcyte, Inc. $PCVX - MarketBeat
Will Vaxcyte Inc. stock keep outperforming rivalsM&A Rumor & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
How Vaxcyte Inc. stock performs during Fed tightening cyclesDay Trade & Safe Capital Allocation Plans - Улправда
How Vaxcyte Inc. stock performs in rate cut cyclesAnalyst Downgrade & Safe Capital Growth Trade Ideas - Улправда
Vaxcyte Enhances Executive Severance to Align With Market - TipRanks
PCVX (Vaxcyte) EV-to-OCF : -7.70 (As of Dec. 19, 2025) - GuruFocus
Profit Review: Will Vaxcyte Inc. stock attract ESG investorsWeekly Risk Summary & Reliable Intraday Trade Plans - DonanımHaber
Vaxcyte enhances executive severance to align with market - MSN
Vaxcyte: Financial Durability And The Case For Disruption (NASDAQ:PCVX) - Seeking Alpha
Market Review: Why Vaxcyte Inc stock could benefit from AI revolution2025 Geopolitical Influence & Fast Moving Stock Watchlists - moha.gov.vn
Pivotal OPUS Phase 3 VAX-31 Head-to-Head Trial Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
How Vaxcyte’s Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors - Yahoo Finance
Vaxcyte (PCVX): Assessing a Discounted Valuation After a Volatile Year in the Share Price - Yahoo Finance
Frazier Life Sciences Management L.P. Reduces Stock Position in Vaxcyte, Inc. $PCVX - MarketBeat
Institutional Investors Bet Big on Vaxcyte’s Clinical Ambitions - AD HOC NEWS
Vaxcyte, Inc. $PCVX Shares Purchased by Eventide Asset Management LLC - MarketBeat
Vaxcyte, Inc. $PCVX Shares Purchased by Maverick Capital Ltd. - MarketBeat
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):